Daniel Lesueur Sells 16,902 Shares of Health Catalyst, Inc. (NASDAQ:HCAT) Stock

Health Catalyst, Inc. (NASDAQ:HCAT) COO Daniel Lesueur sold 16,902 shares of Health Catalyst stock in a transaction that occurred on Wednesday, March 5th. The shares were sold at an average price of $4.52, for a total value of $76,397.04. Following the completion of the sale, the chief operating officer now directly owns 216,250 shares in the company, valued at approximately $977,450. This represents a 7.25 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through the SEC website.

Daniel Lesueur also recently made the following trade(s):

• On Wednesday, February 5th, Daniel Lesueur sold 5,209 shares of Health Catalyst stock. The shares were sold at an average price of $5.76, for a total transaction of $30,003.84.
• On Monday, January 6th, Daniel Lesueur sold 5,209 shares of Health Catalyst stock. The stock was sold at an average price of $7.51, for a total transaction of $39,119.59.

Health Catalyst Stock Performance

Shares of HCAT stock traded down $0.32 during trading on Monday, reaching $3.97. 1,010,415 shares of the company’s stock traded hands, compared to its average volume of 898,193. Health Catalyst, Inc. has a 1 year low of $3.76 and a 1 year high of $9.24. The firm’s 50-day moving average is $5.73 and its 200 day moving average is $7.16. The company has a current ratio of 1.41, a quick ratio of 1.41 and a debt-to-equity ratio of 0.32. The company has a market capitalization of $278.74 million, a P/E ratio of -2.94 and a beta of 1.41.

Institutional Investors Weigh In On Health Catalyst

Institutional investors and hedge funds have recently modified their holdings of the company. Group One Trading LLC raised its stake in Health Catalyst by 107.6% in the fourth quarter. Group One Trading LLC now owns 4,360 shares of the company’s stock valued at $31,000 after purchasing an additional 2,260 shares in the last quarter. Creative Planning increased its stake in Health Catalyst by 13.2% in the 3rd quarter. Creative Planning now owns 21,348 shares of the company’s stock worth $174,000 after purchasing an additional 2,486 shares during the period. Two Sigma Securities LLC lifted its position in Health Catalyst by 19.5% in the fourth quarter. Two Sigma Securities LLC now owns 17,510 shares of the company’s stock valued at $124,000 after purchasing an additional 2,862 shares during the last quarter. Legato Capital Management LLC boosted its stake in shares of Health Catalyst by 3.7% during the fourth quarter. Legato Capital Management LLC now owns 87,992 shares of the company’s stock valued at $622,000 after purchasing an additional 3,171 shares during the period. Finally, Quantbot Technologies LP bought a new position in Health Catalyst in the 4th quarter worth $29,000. 85.00% of the stock is owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

HCAT has been the subject of several recent research reports. Canaccord Genuity Group reduced their price target on Health Catalyst from $11.00 to $10.00 and set a “buy” rating for the company in a research report on Tuesday, January 21st. Wells Fargo & Company decreased their target price on Health Catalyst from $13.00 to $10.00 and set an “overweight” rating on the stock in a report on Tuesday, January 21st. Stifel Nicolaus cut their price objective on shares of Health Catalyst from $10.00 to $5.00 and set a “hold” rating for the company in a research report on Thursday, February 27th. Royal Bank of Canada decreased their price target on shares of Health Catalyst from $7.00 to $6.00 and set a “sector perform” rating on the stock in a research note on Thursday, February 27th. Finally, Piper Sandler dropped their price objective on Health Catalyst from $12.00 to $8.00 and set an “overweight” rating for the company in a report on Tuesday, February 11th. Three analysts have rated the stock with a hold rating and eight have given a buy rating to the company. Based on data from MarketBeat, Health Catalyst has an average rating of “Moderate Buy” and an average target price of $9.27.

About Health Catalyst

Health Catalyst, Inc provides data and analytics technology and services to healthcare organizations in the United States. It operates in two segments, Technology and Professional Services. The company provides data operating system data platform which provides clients single comprehensive environment to integrate and organize data from their disparate software systems; and analytics applications, a software analytics applications build for data platform to analyze clients face across clinical and quality, population health, and financial and operational use cases.